Patents by Inventor Bertolt Kreft

Bertolt Kreft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240424127
    Abstract: The present disclosure relates to IL-7 polypeptides, compositions comprising IL-7 polypeptides, methods of making the same, and methods of using the IL-7 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the IL-7 polypeptides. In some embodiments, the disclosed IL-7 polypeptides comprise at least one modification at an amino acid residue which reduces the affinity of the IL-7 polypeptide to the IL-7 receptor. Also provided herein are synthetic IL-7 polypeptides and methods of manufacture thereof. Further provided herein are immunocytokines comprising immune checkpoint inhibitor molecules, such as anti-PD-1 antibodies, couple to the IL-7 polypeptides provided herein.
    Type: Application
    Filed: January 10, 2024
    Publication date: December 26, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Matilde ARÉVALO-RUIZ, Eric ARMENTANI
  • Patent number: 12173062
    Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.
    Type: Grant
    Filed: July 9, 2022
    Date of Patent: December 24, 2024
    Assignee: Bright Peak Therapeutics AG
    Inventors: Bertolt Kreft, Vijaya Raghavan Pattabiraman, Rubén Alvarez Sanchez, Magali Muller, Jean-Philippe Carralot
  • Publication number: 20240417436
    Abstract: The present disclosure relates activatable immunocytokines targeted to immune checkpoint molecules such as PD-1, compositions comprising the activatable immunocytokines, and methods of use thereof. The present disclosure also relates activatable IL-2 polypeptides linked to anti-PD-1 polypeptides (e.g., anti-PD-1 antibodies).
    Type: Application
    Filed: January 11, 2024
    Publication date: December 19, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Grégory UPERT, Matilde ARÉVALO-RUIZ, Nina RESCHKE, Davor BAJIC, Olivier BORNERT, Arnaud GOEPFERT
  • Publication number: 20240400614
    Abstract: The present disclosure relates to cleavable peptides, including multi-protease cleavable peptides, and methods of use thereof. The cleavable peptides are useful in a variety of applications, including as conditional linkers between two groups and as conditional activators of proteins. The present disclosure also relates to a composition of conditionally regulated proteins with cleavable peptides for treatment of diseases including but not limited to cancer. The conditional activation of proteins is based on cleavable polypeptides that regulate the protein activity.
    Type: Application
    Filed: January 11, 2024
    Publication date: December 5, 2024
    Inventors: Bertolt KREFT, Vijaya Raghavan PATTABIRAMAN, Arnaud GOEPFERT, Grégory UPERT, Tiziano ONGARO, Matilde ARÉVALO-RUIZ
  • Publication number: 20240376170
    Abstract: The present disclosure relates to activatable proteins which comprise cleavable moieties attached thereto which display an altered activity upon cleavage of the cleavable moieties. The present disclosure also relates to activatable IL-2 polypeptides which comprise cleavable moieties, as well as compositions and methods of use thereof. The present disclosure further relates to cleavable peptides which can be cleaved by multiple proteases, as well as to polypeptides incorporating said cleavable peptides.
    Type: Application
    Filed: January 11, 2024
    Publication date: November 14, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Grégory UPERT, Matilde ARÉVALO-RUIZ, Nina RESCHKE, Davor BAJIC, Roy MEODED
  • Publication number: 20240158537
    Abstract: The present disclosure relates to modified anti-PD-1 polypeptides linked to IL-7, pharmaceutical compositions comprising modified anti-PD-1 polypeptides linked to IL-7, methods of making anti-PD-1 polypeptides linked to IL-7, and methods of using the modified anti-PD-1 polypeptides linked to IL-7 for treatment of diseases. In one aspect, the disclosure relates to methods of treating cancer in a subject using the modified anti-PD-1 polypeptides linked to IL-7. Also provided herein is synthetic IL-7 and methods of manufacture thereof.
    Type: Application
    Filed: July 9, 2022
    Publication date: May 16, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Rubén ALVAREZ SANCHEZ, Magali MULLER, Matilde ARÉVALO-RUIZ
  • Publication number: 20240132563
    Abstract: The present disclosure relates to bifunctional cytokine compositions comprising first and second cytokines connected by a linker, as well as methods of making bifunctional cytokine compositions. The disclosure also relates to bifunctional cytokine compositions comprising interleukins, including interleukin-2, interleukin-7, and interleukin-18, as well as derivatives thereof.
    Type: Application
    Filed: February 23, 2023
    Publication date: April 25, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Philipp MOOSMANN
  • Publication number: 20240116997
    Abstract: The present disclosure relates to activatable IL-18 polypeptides, compositions comprising activatable IL-18 polypeptides, methods of making the same, and methods of using the activatable IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the activatable IL-18 polypeptides.
    Type: Application
    Filed: February 23, 2023
    Publication date: April 11, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Arnaud GOEPFERT, Tiziano ONGARO
  • Publication number: 20230355795
    Abstract: The present disclosure relates to modified immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens and IL-18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of immunocytokine compositions.
    Type: Application
    Filed: February 23, 2023
    Publication date: November 9, 2023
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Arnaud GOEPFERT, Kea MARTIN, Andrew CHI
  • Publication number: 20230357342
    Abstract: The present disclosure relates a modified interleukin 18 (IL-18) polypeptide, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases including cancer. The modified IL-18 polypeptide can exhibit an ability to induce interferon gamma (IFN?) production when in contact with a cell, exhibit a diminished ability to be inhibited by IL-18 binding protein (IL-18BP) compared to wild type IL-18 (WT IL-18), and exhibit a ratio of half-maximal inhibitory concentration (IC50) by IL-18BP to half-maximal effective concentration (EC50) to induce IFN? production which is greater than that of WT IL-18.
    Type: Application
    Filed: February 23, 2023
    Publication date: November 9, 2023
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Arnaud GOEPFERT, Tiziano ONGARO, Jean-Philippe CARRALOT, Philipp MOOSMANN, Régis BOEHRINGER, Benoit HORNSPERGER, Roy MEODED, Kea MARTIN, Camille DELON, Andrew CHI
  • Publication number: 20230303649
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases including autoimmune diseases. In one aspect, the disclosure relates to the treatment of autoimmune diseases using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit enhanced binding to IL-2 receptor ? and/or reduced binding to IL-2 receptor ?. In another aspect, the modified IL-2 polypeptides exhibit enhanced ability to activate T regulatory cells compared to T effector cells.
    Type: Application
    Filed: July 9, 2022
    Publication date: September 28, 2023
    Inventors: Bertolt KREFT, Vijaya Raghavan PATTABIRAMAN, Rubén ALVAREZ SANCHEZ, Magali MULLER, Jean-Philippe CARRALOT
  • Publication number: 20230250181
    Abstract: The present disclosure relates to modified anti-PD-1 polypeptides, pharmaceutical compositions comprising modified anti-PD-1 polypeptides, methods of making anti-PD-1 polypeptides, and methods of using the modified anti-PD-1 polypeptides for treatment of diseases. In one aspect, the disclosure relates to methods of treating cancer in a subject using the modified anti-PD-1 polypeptides.
    Type: Application
    Filed: July 9, 2022
    Publication date: August 10, 2023
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Rubén ALVAREZ SANCHEZ, Magali MULLER, Matilde ARÉVALO-RUIZ
  • Publication number: 20230201365
    Abstract: The present disclosure relates to modified anti-CD20 polypeptides, compositions comprising modified anti-CD20 polypeptides, methods of making the same, and methods of using the modified anti-CD20 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified anti-CD20 polypeptides.
    Type: Application
    Filed: July 9, 2022
    Publication date: June 29, 2023
    Inventors: Bertolt KREFT, Vijaya Raghavan PATTABIRAMAN, Jean-Philippe CARRALOT
  • Publication number: 20230201364
    Abstract: The present disclosure relates to conjugate compositions comprising an antibody or an antigen binding fragment, a synthetic protein, and a linker. The disclosure further relates to methods of making the conjugate compositions and to methods of using the conjugate compositions for the treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the conjugate compositions.
    Type: Application
    Filed: July 9, 2022
    Publication date: June 29, 2023
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Rubén ALVAREZ SANCHEZ, Magali MULLER, Matilde ARÉVALO-RUIZ
  • Publication number: 20230183331
    Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.
    Type: Application
    Filed: July 9, 2022
    Publication date: June 15, 2023
    Inventors: Bertolt KREFT, Vijaya Raghavan PATTABIRAMAN, Rubén ALVAREZ SANCHEZ, Magali MULLER, Jean-Philippe CARRALOT
  • Publication number: 20230181754
    Abstract: The present disclosure relates to modified anti-PD-L1 polypeptides, compositions comprising modified anti-PD-L1 polypeptides, methods of making the same, and methods of using the modified anti-PD-L1 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified anti-PD-L1 polypeptides.
    Type: Application
    Filed: July 9, 2022
    Publication date: June 15, 2023
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Jean-Philippe CARRALOT, Rubén ALVAREZ SANCHEZ
  • Publication number: 20220056091
    Abstract: The present disclosure relates to modified IL-18 polypeptides, compositions comprising modified IL-18 polypeptides, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-18 polypeptides. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN?. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN? without being neutralized by IL-18 binding protein.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 24, 2022
    Inventors: Vijaya Raghavan PATTABIRAMAN, Jean-Philippe CARRALOT, Bertolt KREFT, Jeffrey William BODE, Régis BOEHRINGER, Matilde ARÉVALO-RUIZ, Camille DELON, Amélie WIEDERKEHR, Claudia FETZ, Anna HAYDN, Alexander FLOHR, Roberto IACONE, Benoit HORNSPERGER, Chongqing WANG
  • Patent number: 8729082
    Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.
    Type: Grant
    Filed: April 24, 2010
    Date of Patent: May 20, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
  • Publication number: 20120128662
    Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.
    Type: Application
    Filed: April 24, 2010
    Publication date: May 24, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach